title: Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib.
abstract: Colorectal cancer is a global issue, affecting men and women equally. Over the last 25 years, advances in therapy and multidisciplinary care have led to improvements in survival for those with colorectal cancer. Despite these advances, more therapeutic options are needed for those being treated for this disease. Regorafenib is an oral drug that is a new therapeutic option for our patients. The CORRECT and CONCUR trials demonstrate the efficacy of regorafenib in the last line setting. This article summarizes some of the regorafenib clinical trial data and discusses the strategies to help manage the side effects of this drug including patient education, dose reductions and interruptions, and monitoring hypertension and liver function.
authors.affiliation: British Columbia Cancer Agency, Vancouver, BC, Canada.
authors.forename: Barbara
authors.initials: B
authors.lastname: Melosky
keywords: Metastatic colorectal cancer; oral therapy; overall survival; progression-free survival; regorafenib; side effect management